199 related articles for article (PubMed ID: 33744409)
1. Pretransplant use of toripalimab for hepatocellular carcinoma resulting in fatal acute hepatic necrosis in the immediate postoperative period.
Chen GH; Wang GB; Huang F; Qin R; Yu XJ; Wu RL; Hou LJ; Ye ZH; Zhang XH; Zhao HC
Transpl Immunol; 2021 Jun; 66():101386. PubMed ID: 33744409
[TBL] [Abstract][Full Text] [Related]
2. Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient?
Nordness MF; Hamel S; Godfrey CM; Shi C; Johnson DB; Goff LW; O'Dell H; Perri RE; Alexopoulos SP
Am J Transplant; 2020 Mar; 20(3):879-883. PubMed ID: 31550417
[TBL] [Abstract][Full Text] [Related]
3. Immune Checkpoint Inhibitors in Patients with Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Case Report and Literature Review.
Qiu J; Tang W; Du C
Curr Cancer Drug Targets; 2020; 20(9):720-727. PubMed ID: 32433005
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant Programmed Cell Death 1 (PD-1) Inhibitor Treatment in Patients With Hepatocellular Carcinoma Before Liver Transplant: A Cohort Study and Literature Review.
Qiao ZY; Zhang ZJ; Lv ZC; Tong H; Xi ZF; Wu HX; Chen XS; Xia L; Feng H; Zhang JJ; Xia Q
Front Immunol; 2021; 12():653437. PubMed ID: 34349755
[TBL] [Abstract][Full Text] [Related]
5. Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma.
Friend BD; Venick RS; McDiarmid SV; Zhou X; Naini B; Wang H; Farmer DG; Busuttil RW; Federman N
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28643391
[TBL] [Abstract][Full Text] [Related]
6. Rescue liver re-transplantation after graft loss due to severe rejection in the setting of pre-transplant nivolumab therapy.
Dehghan Y; Schnickel GT; Hosseini M; Burgoyne AM; Ajmera VH; Morris GP; Mendler MH; Parekh JR; Abushamat F; Vodkin I; Kono Y
Clin J Gastroenterol; 2021 Dec; 14(6):1718-1724. PubMed ID: 34643885
[TBL] [Abstract][Full Text] [Related]
7. Stable liver graft post anti-PD1 therapy as a bridge to transplantation in an adolescent with hepatocellular carcinoma.
Kang E; Martinez M; Moisander-Joyce H; Saenger YM; Griesemer AD; Kato T; Yamashiro DJ; Remotti H; Gartrell RD
Pediatr Transplant; 2022 May; 26(3):e14209. PubMed ID: 34907641
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant programmed cell death 1 inhibitor before liver transplantation for HCC is not associated with increased graft loss.
Wang T; Chen Z; Liu Y; Jia Y; Ju W; Chen M; Zhao Q; Wang D; Guo Z; Tang Y; He X
Liver Transpl; 2023 Jun; 29(6):598-606. PubMed ID: 36747346
[TBL] [Abstract][Full Text] [Related]
9. Complete pathologic response to pretransplant locoregional therapy for hepatocellular carcinoma defines cancer cure after liver transplantation: analysis of 501 consecutively treated patients.
Agopian VG; Morshedi MM; McWilliams J; Harlander-Locke MP; Markovic D; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Hiatt JR; Busuttil RW
Ann Surg; 2015 Sep; 262(3):536-45; discussion 543-5. PubMed ID: 26258323
[TBL] [Abstract][Full Text] [Related]
10. An immune function assay predicts post-transplant recurrence in patients with hepatocellular carcinoma.
Cheng JW; Shi YH; Fan J; Huang XW; Qiu SJ; Xiao YS; Wang Z; Dai Z; Tang ZY; Zhou J
J Cancer Res Clin Oncol; 2011 Oct; 137(10):1445-53. PubMed ID: 21809031
[TBL] [Abstract][Full Text] [Related]
11. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma.
Schnitzbauer AA; Zuelke C; Graeb C; Rochon J; Bilbao I; Burra P; de Jong KP; Duvoux C; Kneteman NM; Adam R; Bechstein WO; Becker T; Beckebaum S; Chazouillères O; Cillo U; Colledan M; Fändrich F; Gugenheim J; Hauss JP; Heise M; Hidalgo E; Jamieson N; Königsrainer A; Lamby PE; Lerut JP; Mäkisalo H; Margreiter R; Mazzaferro V; Mutzbauer I; Otto G; Pageaux GP; Pinna AD; Pirenne J; Rizell M; Rossi G; Rostaing L; Roy A; Turrion VS; Schmidt J; Troisi RI; van Hoek B; Valente U; Wolf P; Wolters H; Mirza DF; Scholz T; Steininger R; Soderdahl G; Strasser SI; Jauch KW; Neuhaus P; Schlitt HJ; Geissler EK
BMC Cancer; 2010 May; 10():190. PubMed ID: 20459775
[TBL] [Abstract][Full Text] [Related]
12. Recipient Hepatic Tumor-Associated Immunologic Infiltrates Predict Outcomes After Liver Transplantation for Hepatocellular Carcinoma.
Atanasov G; Dino K; Schierle K; Dietel C; Aust G; Pratschke J; Seehofer D; Schmelzle M; Hau HM
Ann Transplant; 2020 Mar; 25():e919414. PubMed ID: 32165607
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitor therapy for malignant tumors in liver transplantation recipients: A systematic review of the literature.
Zhang P; Zhu G; Li L; Lai G; Wang Z; Sun C; Xia W; Wu L
Transplant Rev (Orlando); 2022 Dec; 36(4):100712. PubMed ID: 35870411
[TBL] [Abstract][Full Text] [Related]
14. Examinations of Factors Influencing Survival of Liver Transplantation for Hepatocellular Carcinoma: A Single-Center Experience From Budapest.
Piros L; Fehérvári I; Görög D; Nemes B; Szabó J; Gerlei Z; Végső G; Kóbori L; Máthé Z
Transplant Proc; 2015 Sep; 47(7):2201-6. PubMed ID: 26361680
[TBL] [Abstract][Full Text] [Related]
15. Liver transplantation for hepatocellular carcinoma following checkpoint inhibitor therapy with nivolumab.
Schnickel GT; Fabbri K; Hosseini M; Misel M; Berumen J; Parekh J; Mekeel K; Dehghan Y; Kono Y; Ajmera V
Am J Transplant; 2022 Jun; 22(6):1699-1704. PubMed ID: 35080128
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of Simultaneous Liver Kidney Transplantation in Patients With Hepatocellular Carcinoma.
Rich N; Tanriover B; Singal AG; Marrero JA
Transplantation; 2017 Jan; 101(1):e12-e19. PubMed ID: 28009759
[TBL] [Abstract][Full Text] [Related]
17. Propensity-Matched Analysis of Patients with Mixed Hepatocellular-Cholangiocarcinoma and Hepatocellular Carcinoma Undergoing Liver Transplantation.
Lunsford KE; Court C; Seok Lee Y; Lu DS; Naini BV; Harlander-Locke MP; Busuttil RW; Agopian VG
Liver Transpl; 2018 Oct; 24(10):1384-1397. PubMed ID: 29573187
[TBL] [Abstract][Full Text] [Related]
18. Extended postinterventional tumor necrosis-implication for outcome in liver transplant patients with advanced HCC.
Kornberg A; Witt U; Matevossian E; Küpper B; Assfalg V; Drzezga A; Hüser N; Wildgruber M; Friess H
PLoS One; 2013; 8(1):e53960. PubMed ID: 23349774
[TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab-induced severe rejection and graft intolerance syndrome resulting in renal allograft nephrectomy.
Padala SA; Patel SK; Vakiti A; Patel N; Gani I; Kapoor R; Muhammad S
J Oncol Pharm Pract; 2021 Mar; 27(2):470-476. PubMed ID: 32580640
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive comparison of three different immunosuppressive regimens for liver transplant patients with hepatocellular carcinoma: steroid-free immunosuppression, induction immunosuppression and standard immunosuppression.
Liu YY; Li CP; Huai MS; Fu XM; Cui Z; Fan LL; Zhang S; Liu Y; Ma J; Li G; Shen ZY
PLoS One; 2015; 10(3):e0120939. PubMed ID: 25816221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
